GAO Recommends Strengthening FDA's Ability to Respond to Shortages - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GAO Recommends Strengthening FDA's Ability to Respond to Shortages


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Government Accountability Office (GAO) issued a report recommending that FDA’s ability to respond to drug shortages be strengthened. The report was released in conjunction with a Senate hearing before the Committee on Health, Education, Labor, and Pensions on Dec. 15, 2011, on the subject of drug shortages. The report reviews trends in prescription drug shortages, identifies the reported causes of selected shortages, describes FDA’s response to drug shortages, and evaluates the extent to which FDA can protect public health through its response to drug shortages.

According to the report, FDA responds to drug shortages by taking actions to address the underlying causes of the shortage and to enhance availability. The report notes that when informed in advance of a potential shortage, FDA has increasingly been able to prevent shortages from occurring. But the report concludes, “FDA is constrained in its ability to protect public health from drug shortages due to its lack of authority to require manufacturers to report actual or potential shortages to the agency or the public, or to require manufacturers to take certain actions to prevent, alleviate, or resolve shortages. As a result, the agency’s approach to managing drug shortages is predominately reactive.”

The GAO recommends that Congress consider establishing a requirement for manufacturers to report any circumstances that could affect the supply of their drugs. In addition, GAO recommends that FDA enhance its ability to respond to potential shortages by developing an information system to manage data about shortages.

See related Pharm Tech article:

Taking Drugs off the Short List (blog post)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here